• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Initiator Pharma

2.86 SEK

+5.93 %

Less than 1K followers

INIT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+5.93 %
-2.72 %
-7.44 %
-3.38 %
-3.38 %
-26.10 %
-59.72 %
-48.76 %
-36.24 %

Initiator Pharma is a biotechnology company developing drug candidates for diseases of the central and peripheral nervous system. The company's main business focus is on the development of drug candidates used in the treatment of erectile dysfunction in men. Initiator Pharma was founded through a spin-off from the company Saniona and is headquartered in Denmark.

Read more
Market cap
195.78M SEK
Turnover
37.01K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
21.8.
2026

Interim report Q2'26

20.11.
2026

Interim report Q3'26

26.2.
2027

Annual report '26

Press release23.06.2026 klo 09.30

Initiator Pharma attends BIO 2026 in San Diego

Initiator Pharma
Regulatory press release29.05.2026 klo 12.55

Initiator Pharma A/S – Resolutions of the annual general meeting 2026

Initiator Pharma
Regulatory press release12.05.2026 klo 11.00

Initiator Pharma A/S calls for the Annual General Meeting

Initiator Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release12.05.2026 klo 10.55

Remuneration report 2025 for Initiator Pharma A/S

Initiator Pharma
Press release11.05.2026 klo 11.00

DNB Carnegie Access: Initiator Pharma: Reassuring progress – Q1 review

Initiator Pharma
Regulatory press release08.05.2026 klo 09.30

INITIATOR PHARMA: Q1 2026 REPORT

Initiator Pharma
Press release29.04.2026 klo 11.31

DNB Carnegie Access: Initiator Pharma: Enrolment on track

Initiator Pharma
Press release28.04.2026 klo 18.30

Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study

Initiator Pharma
Regulatory press release28.04.2026 klo 12.00

Annual report 2025 for Initiator Pharma A/S

Initiator Pharma
Press release21.04.2026 klo 14.18

Redeye: Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued

Initiator Pharma
Press release17.04.2026 klo 13.31

DNB Carnegie Access: Initiator Pharma: All in on pudafensine

Initiator Pharma
Press release17.04.2026 klo 09.30

Initiator Pharma to fully prioritize pudafensine

Initiator Pharma
Press release10.04.2026 klo 12.40

Initiator Pharma to present at Redeye Healthcare Day 2026

Initiator Pharma
Press release23.02.2026 klo 12.56

DNB Carnegie Access: Initiator Pharma: Moving in the right direction – Q4 review

Initiator Pharma
Press release20.02.2026 klo 17.26

Redeye: Initiator Pharma (Q4 Review): Dosing underway in phase IIa study

Initiator Pharma
Regulatory press release20.02.2026 klo 09.30

INITIATOR PHARMA: Q4 2025 REPORT

Initiator Pharma
Press release18.02.2026 klo 16.00

Initiator Pharma granted European patent for pudafensine in Female Sexual Dysfunction, including vulvodynia

Initiator Pharma
Press release23.12.2025 klo 16.27

DNB Carnegie Access: Initiator Pharma: Vulvodynia study enrolment has started

Initiator Pharma
Press release23.12.2025 klo 09.31

Initiator Pharma to attend J.P. Morgan Healthcare Conference in San Francisco

Initiator Pharma
Press release23.12.2025 klo 09.30

Initiator Pharma initiates patient enrollment in Phase IIa vulvodynia study

Initiator Pharma